USPTO Examiner JUSTICE GINA CHIEUN YU - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18898561ANTIBACTERIAL CONDUCTIVE SELF-HEALING HYDROGELSeptember 2024December 2024Allow200NoNo
18720721EFFECT PIGMENTS HAVING A REFLECTIVE CORE AND SEMICONDUCTOR LAYERSJune 2024March 2025Allow910NoNo
18593225MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEENMarch 2024February 2025Allow1110YesNo
18474052MINOXIDIL ADJUVANT THERAPIESSeptember 2023April 2025Abandon1810NoNo
18467858TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONSeptember 2023December 2024Allow1510NoNo
18456625SKIN CARE COMPOSITIONAugust 2023August 2024Allow1110NoNo
18233853GANCICLOVIR COMPOSITIONS AND RELATED METHODSAugust 2023December 2024Abandon1610NoNo
18366907Hemp Oil/Magnesium Preparation for Cognitive-Enhancement and Reduction of Stress and lnflammationAugust 2023December 2024Abandon1610NoNo
18218954COMPOSITION AND METHOD OF TREATING CONDITIONS ASSOCIATED WITH EXTRACELLULAR MATRIX DYSFUNCTION BY ADMINISTERING MICRONUTRIENT COMPOSITIONJuly 2023April 2024Allow1020YesNo
18196617ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENTMay 2023August 2023Allow310NoNo
18112781pH TRIGGERED RELEASE PARTICLEFebruary 2023March 2024Allow1320NoNo
18110079Embossed Effect Pigment and Method of Manufacture of Embossed Effect PigmentFebruary 2023May 2024Allow1510NoNo
18163818EXTENDED RELEASE AMPHETAMINE TABLETSFebruary 2023April 2024Allow1510NoNo
18075863TOPICAL MUSCLE RELAXATION COMPOSITIONS AND METHODSDecember 2022March 2024Allow1620YesNo
18008191ULTRASONIC PREPARATION METHOD OF PROTEIN-DERIVED PEPTIDE-POLYSACCHARIDE NANOPARTICLES LOADED WITH BIOACTIVE COMPONENTSDecember 2022September 2024Abandon2210NoNo
17928181GINGER WATER COMPOSITION HAVING GINGER EXTRACT AND METHOD FOR MANUFACTURING THE SAMENovember 2022June 2023Allow600NoNo
18055945OPHTHALMIC COMPOSITIONNovember 2022October 2023Allow1110NoNo
18055940OPHTHALMIC COMPOSITIONNovember 2022August 2023Allow910NoNo
18055949OPHTHALMIC COMPOSITIONNovember 2022October 2023Allow1110NoNo
17896474ADHESION-PREVENTING COMPOSITIONAugust 2022September 2023Allow1310NoNo
17890122Shear-Thinning Cosmetic CompositionAugust 2022September 2023Allow1310NoNo
17820003SETTABLE SURGICAL IMPLANTS AND THEIR PACKAGINGAugust 2022May 2025Allow3320NoNo
17819159TOPICAL SKIN TREATMENT COMPOSITIONAugust 2022July 2024Abandon2310NoNo
17879797ARTIFICIAL DRESSING AND USE OF ARTIFICIAL DRESSING FOR PROMOTING WOUND HEALINGAugust 2022March 2024Allow1910NoNo
17875236FOAMING CLEANSERJuly 2022July 2024Allow2330YesNo
17794072Alginate Based Particles as a Temporary Embolic AgentJuly 2022April 2024Allow2110YesNo
17861658BIOLOGICAL PESTICIDE FUNGUS EFFECTIVE AGAINST MULTIPLE DIFFERENT SPECIES OF INSECTJuly 2022June 2024Allow2321YesNo
17841284GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMSJune 2022December 2023Allow1810NoNo
17830039METHOD AND COMPOSITION FOR REJUVENATION OF MUSCLE CELLSJune 2022April 2024Abandon2310NoNo
17780789COMPOSITIONS AND METHODS FOR BIOREMEDIATION OF GLYPHOSATE CONTAINING SUBSTRATESMay 2022May 2025Allow3600NoNo
17742960DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAMEMay 2022January 2023Allow810NoNo
17772728ANTI-AGING CHINESE HERB EXTRACT,EXTRACTION METHOD AND USE THEREOFApril 2022March 2025Allow3411YesNo
17754891METHOD FOR PREPARING AN INVERSE EMULSION COMPRISING TWO CATIONIC POLYMERSApril 2022February 2023Allow1000NoNo
17659185SUPPLEMENT FOR MITIGATING WOMAN'S DISORDERS CAUSED BY AGEINGApril 2022February 2024Allow2220NoNo
17767194METHOD OF PREPARING A COSMETIC COMPONENTApril 2022June 2024Allow2700NoNo
17707507Personalized Nutritional Supplements and Methods of MakingMarch 2022February 2024Allow2350YesNo
17655470TREATMENT OF HEPATITIS DELTA VIRUS INFECTIONMarch 2022June 2023Allow1510NoNo
17640451USE OF A COMPOSITION CONTAINING AN EXTRACT OF TULIPA GESNERIANAMarch 2022April 2025Abandon3711NoNo
17685666FOOD SUPPLEMENT FOR ORAL ADMINISTRATIONMarch 2022May 2024Abandon2610NoNo
17678178CHEWABLE PHARMACEUTICAL PRODUCT FOR DELIVERY OF COLESEVELAM HYDROCHLORIDEFebruary 2022September 2023Allow1820YesNo
17586414COMPOSITION FOR PREVENTION OR TREATMENT OF OCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEIJanuary 2022April 2022Allow300NoNo
17582237SKIN CARE SERUM CONTAINING SODIUM HYALURONATEJanuary 2022April 2024Abandon2720NoNo
17627926PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, CONTAINING BENTONITE AS ACTIVE INGREDIENTJanuary 2022June 2024Abandon2950NoNo
17577479FORMULATIONS OF AG10January 2022February 2024Allow2420NoNo
17559068CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITISDecember 2021August 2024Allow3220NoNo
17559580METHOD, COMPOSITION AND PACKAGE FOR BOWEL CLEANSINGDecember 2021October 2023Abandon2101NoNo
17556896INTERNAL TEAT SEALANTS AND THEIR USE IN THE PREVENTION OF BOVINE MASTITIS IN THE DRY COWBDecember 2021August 2023Abandon2010NoNo
17549980Method of Treating Oxidative Stress in Skin and Compositions ThereforDecember 2021February 2024Allow2621NoNo
17545178THERAPEUTIC SYSTEMS, DEVICES, AND COMPOSITIONS WITH WOUND HEALING AND TISSUE REGENERATIVE PROPERTIES, USES THEREOF, AND CORRESPONDING METHODSDecember 2021January 2024Allow2551YesNo
17530027COMPOSITIONS OF MIDODRINE AND METHODS OF USING THE SAMENovember 2021December 2023Allow2511NoNo
17527377OILY SOLID COSMETIC, METHOD FOR PRODUCING THE OILY SOLID COSMETIC, AND METHOD FOR PRODUCING MOLDED PRODUCT USING THE OILY SOLID COSMETICNovember 2021December 2023Abandon2511NoNo
17610500MICROPARTICLE COMPOSITIONS COMPRISING SAFLUFENACILNovember 2021April 2025Allow4110NoNo
17609955HERBICIDAL COMPOSITIONNovember 2021June 2024Allow3200NoNo
17606402COMPOUND COMPRISING A FUNCTIONAL AGENT, AND RELATED MANUFACTURING METHODOctober 2021June 2025Allow4311NoNo
17508908Herbicide Compatibility ImprovementOctober 2021July 2025Allow4402NoNo
17605104COMBINATION OF MODIFIED STARCH/C13-C15 FATTY ACID/CLAYOctober 2021September 2024Allow3511YesNo
17504087ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENTOctober 2021December 2023Allow2611NoNo
17474322SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONISTSeptember 2021January 2024Allow2820NoNo
17433906COATING COMPOSITION FOR SEEDAugust 2021April 2025Abandon4311NoNo
17401777HYPOCHLOROUS ACID-BASED EYELID CLEANSERSAugust 2021August 2023Allow2420NoNo
17389917METHODS OF DYEING KERATIN FIBERS WITH A PIGMENT DYEING COMPOSITIONJuly 2021July 2024Allow3620YesNo
17427082COMPOSITION FOR TREATING HAIR LOSS OR PROMOTING HAIR GROWTH COMPRISING GROWTH FACTORJuly 2021January 2025Abandon4211NoNo
17384227COLON CLEANSING COMPOSITIONS AND METHOD OF USEJuly 2021May 2024Allow3330YesNo
17425004MULTIPURPOSE BIOLOGICAL COMPOSITIONSJuly 2021January 2025Abandon4201NoNo
17379147Shear-Thinning Therapeutic Composition, and Related MethodsJuly 2021December 2024Allow4122YesNo
17377477COMPOSITIONS AND TREATMENTS FOR KERATINOUS MATERIALS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITSJuly 2021July 2023Abandon2401NoNo
17423440ANTIMICROBIAL COMPOSITION WITH PROCOAGULANT, IMMUNOMODULATORY, AND TISSUE REGENERATIVE PROPERTIESJuly 2021August 2024Abandon3760YesYes
17361123IMPLANTABLE MEDICAL DEVICES WITH INCREASED IMMUNE TOLERANCE, AND METHODS FOR MAKING AND IMPLANTINGJune 2021July 2023Abandon2501NoNo
17415194Biofertilizing Bacterial StrainJune 2021December 2024Allow4210NoNo
17299968METHOD FOR PRODUCING AN ASPARAGOPSIS OIL COMPOSITIONJune 2021December 2024Allow4211YesNo
17327135DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USING THE SAMEMay 2021March 2023Allow2210NoNo
17326830NUTRITIONAL SUPPLEMENT TO COMBAT COVID-19 AND AID VACCINATIONMay 2021March 2022Abandon1010YesNo
17319063SHEAR-THINNING COSMETIC COMPOSITIONMay 2021May 2022Allow1210YesNo
17316577USE OF TRIENTINE TO DELIVER COPPER TO ISCHEMIC TISSUEMay 2021April 2024Allow3621YesNo
17291508Encapsulation of Cyclohexanediones Process and ProductMay 2021May 2025Allow4811NoNo
17288452pH-Triggered Therapeutical Wound DressingApril 2021December 2023Allow3211NoNo
17288380pH-Triggered Diagnostic Wound DressingApril 2021December 2023Allow3111NoNo
17286999ALGAL EXTRACT FOR USE IN THE TREATMENT OR PREVENTION OF POST-TRAUMATIC IMMUNOSUPPRESSIONApril 2021March 2025Allow4720NoNo
17285291INHIBITOR OF RENAL FIBROSIS IN DIABETIC NEPHROPATHYApril 2021November 2024Abandon4310NoNo
17285264AGENT FOR IMPROVING QUALITY OF SLEEPApril 2021December 2024Abandon4420NoNo
17284954AGENT FOR SUPPRESSING ALCOHOL SICKNESS OR HANGOVER DUE TO ALCOHOLIC BEVERAGE INGESTIONApril 2021November 2024Abandon4320NoNo
17284862METHOD FOR RENAL PROTECTIONApril 2021March 2025Allow4720NoNo
16068669NANOBODY PREPARATION SYSTEM FOR ADMINISTRATION THROUGH INTERNAL AND EXTERNAL EPIDERMIS OF HEAD AND NECK AND PREPARATION METHOD AND USEApril 2021May 2024Abandon6001NoNo
17284222SEAWEED FLOURApril 2021January 2025Allow4510NoNo
17225163COMPOSITIONS AND METHODS FOR TREATING NON-CORNIFIED EPITHELIAL TISSUE OF A FEMALE BODYApril 2021October 2022Abandon1910NoNo
17282833COMPOSITION FOR IMPROVING BIOAVAILABILITY OF DRUGSApril 2021April 2024Allow3610NoNo
17222579GHB FORMULATION AND METHOD FOR ITS MANUFACTUREApril 2021May 2022Allow1321YesNo
17250960Emulsion-Based Personal Care Compositions and Methods for the SameApril 2021February 2025Allow4730NoNo
17282581TCA CYCLE INTERMEDIATES AND METHODS OF USE THEREOFApril 2021May 2024Abandon3710NoNo
17281670COMPOSITIONS COMPRISING CBD FOR TREATING ANORECTAL DISORDERSMarch 2021October 2023Allow3000NoNo
17211119CORTICOSTEROID CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR EOSINOPHILIC ESOPHAGITISMarch 2021September 2021Allow610YesNo
17279296TOPICAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALT THEREOFMarch 2021January 2025Allow4651YesNo
17275461MESOSTIGMATA MITE CONTROL COMPOSITIONMarch 2021June 2025Allow5131NoNo
17274918DRUG DELIVERY SYSTEMMarch 2021September 2024Allow4221YesNo
17195074CHLORITE-CONTAINING COMPOSITIONSMarch 2021January 2024Abandon3520NoNo
17272914COMPOSITION FOR PROMOTING HAIR GROWTH COMPRISING ADIPONECTIN-DERIVED PEPTIDEMarch 2021June 2023Allow2711NoNo
17270602FAT ACCUMULATION INHIBITOR AND BLOOD LIPID LEVEL IMPROVING AGENTFebruary 2021January 2025Abandon4730YesNo
17270630NEW THERAPY FOR INFLAMMATORY LINEAR VERRUCOUS EPIDERMAL NEVUS (ILVEN)February 2021March 2024Allow3610NoNo
17173234DISINFECTANT CLEANING COMPOSITIONS AND METHODS OF USE THEREOFFebruary 2021March 2025Abandon5020NoYes
17267608ANACARDIC ACID FOR NEURAL REPAIRFebruary 2021April 2024Allow3901NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JUSTICE, GINA CHIEUN YU.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
49
Examiner Affirmed
38
(77.6%)
Examiner Reversed
11
(22.4%)
Reversal Percentile
34.9%
Lower than average

What This Means

With a 22.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
188
Allowed After Appeal Filing
31
(16.5%)
Not Allowed After Appeal Filing
157
(83.5%)
Filing Benefit Percentile
16.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner JUSTICE, GINA CHIEUN YU - Prosecution Strategy Guide

Executive Summary

Examiner JUSTICE, GINA CHIEUN YU works in Art Unit 1617 and has examined 1,083 patent applications in our dataset. With an allowance rate of 51.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner JUSTICE, GINA CHIEUN YU's allowance rate of 51.9% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by JUSTICE, GINA CHIEUN YU receive 2.41 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by JUSTICE, GINA CHIEUN YU is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a -5.1% benefit to allowance rate for applications examined by JUSTICE, GINA CHIEUN YU. This interview benefit is in the 3% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.2% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 36.3% of cases where such amendments are filed. This entry rate is in the 47% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 90.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 66% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 59.8% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 58.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 67.8% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 4.3% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.6% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.